Compare ADSK & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADSK | BDX |
|---|---|---|
| Founded | 1982 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.3B | 51.5B |
| IPO Year | 1994 | 1994 |
| Metric | ADSK | BDX |
|---|---|---|
| Price | $239.39 | $155.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 11 |
| Target Price | ★ $338.88 | $189.60 |
| AVG Volume (30 Days) | 1.8M | ★ 2.3M |
| Earning Date | 02-26-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.73% |
| EPS Growth | ★ 2.15 | N/A |
| EPS | ★ 5.23 | 1.34 |
| Revenue | $7,206,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $15.10 | N/A |
| Revenue Next Year | $10.33 | $2.22 |
| P/E Ratio | ★ $47.35 | $115.32 |
| Revenue Growth | ★ 17.53 | 8.24 |
| 52 Week Low | $215.01 | $153.75 |
| 52 Week High | $329.09 | $231.82 |
| Indicator | ADSK | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 26.09 |
| Support Level | $215.51 | N/A |
| Resistance Level | $262.07 | $195.22 |
| Average True Range (ATR) | 6.31 | 3.40 |
| MACD | -0.64 | -0.06 |
| Stochastic Oscillator | 7.68 | 9.96 |
Founded in 1982, Autodesk is a multinational software company best known for pioneering computer-aided design, or CAD, with its AutoCAD product. Nowadays, Autodesk provides design software for a variety of verticals, including architecture & construction, manufacturing, and media & entertainment. Autodesk products have been used in some of the world's most iconic landmarks, like Burj Khalifa, and well-known movie titles like Avatar.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.